An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
A case series described two 58-year-old women, who developed secondary or autoimmune pulmonary alveolar proteinosis during treatment with ciclosporin [cyclosporine A], cyclophosphamide and prednisolone for dermatomyositis with interstitial lung disease.
Case 1: A 58-year-old woman was hospitalised for dermatomyositis with interstitial lung disease and was initiated on ciclosporin 3 mg/kg/day, prednisolone 1 mg/kg/day [routes not stated] and IV cyclophosphamide 500 mg/m2. The dose of ciclosporin was adjusted in accordance with the 12-hour trough level within 200 ng/mL and a concentration between 700 to 1000 ng/mL after 2 hours. Cyclophosphamide was administered at intervals of 2 weeks for the first six doses, followed by an interval of one-to-two months, with dose adjustments in...
- Imura Y, et al. Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. Modern rheumatology / the Japan Rheumatism Association 28: 724-729, No. 4, 4 Jul 2018. Available from: URL: http://doi.org/10.3109/14397595.2016.1153443 - JapanCrossRefGoogle Scholar